Enzychem Lifesciences Corporation (KOSDAQ:183490)

Market Cap	89.51B
Revenue (ttm)	75.92B
Net Income (ttm)	-22.88B
Shares Out	77.63M
EPS (ttm)	-285.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155,844
Average Volume	163,973
Open	1,082.00
Previous Close	1,093.00
Day's Range	1,066.00 - 1,085.00
52-Week Range	992.00 - 2,030.00
Beta	1.55
RSI	36.01
Earnings Date	Aug 14, 2025

About Enzychem Lifesciences

Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 127
• Stock Exchange: KOSDAQ
• Ticker Symbol: 183490

Financial Performance

In 2024, Enzychem Lifesciences's revenue was 77.38 billion, an increase of 1.76% compared to the previous year's 76.04 billion. Losses were -22.11 billion, 137.0% more than in 2023.